Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Trang T Ly

Showing results (51-60 of 65) with videos related to

Pageof 7
Sort By:
Diabetes Technology & Therapeutics|May 17, 2019
Hybrid Closed-Loop Control Is Safe and Effective for People with Type 1 Diabetes Who Are at Moderate to High Risk for HypoglycemiaStacey M Anderson, Bruce A Buckingham, Marc D Breton, et al.
Pediatric Diabetes|November 22, 2017
Predictive hyperglycemia and hypoglycemia minimization: In-home double-blind randomized controlled evaluation in children and young adolescentsGregory P Forlenza, Dan Raghinaru, Faye Cameron, et al.
Diabetes Technology & Therapeutics|August 14, 2023
Automated Insulin Delivery with Remote Real-Time Continuous Glucose Monitoring for Hospitalized Patients with Diabetes: A Multicenter, Single-Arm, Feasibility TrialGeorgia M Davis, Michael S Hughes, Sue A Brown, et al.
Diabetes, Obesity & Metabolism|September 20, 2024
Psychosocial outcomes with the Omnipod® 5 Automated Insulin Delivery System in caregivers of very young children with type 1 diabetesSarah A MacLeish, Korey K Hood, William H Polonsky, et al.
The Lancet. Diabetes & Endocrinology|February 26, 2026
Tubeless automated insulin delivery versus multiple daily injections in children and adults with type 1 diabetes with elevated HbA<sub>1c</sub> (RADIANT): a multicentre, international, parallel-group, open-label, randomised, controlled trialEmma G Wilmot, Jacques Beltrand, Bruno Guerci, et al.
Diabetes Care|July 18, 2025
Use of the Omnipod 5 Automated Insulin Delivery System Activity Feature Reduces Insulin Delivery and Attenuates the Drop in Glycemia Associated With Exercise in a Randomized Controlled TrialLauren V Turner, Jennifer L Sherr, Dessi P Zaharieva, et al.
Pediatric Diabetes|April 30, 2025
Psychosocial Outcomes with the Omnipod® 5 Automated Insulin Delivery System in Children and Adolescents with Type 1 Diabetes and Their CaregiversKorey K Hood, William H Polonsky, Sarah A MacLeish, et al.
Diabetes Research and Clinical Practice|July 19, 2022
How introduction of automated insulin delivery systems may influence psychosocial outcomes in adults with type 1 diabetes: Findings from the first investigation with the Omnipod® 5 SystemWilliam H Polonsky, Korey K Hood, Carol J Levy, et al.
Diabetes Technology & Therapeutics|December 17, 2016
Feasibility of Long-Term Closed-Loop Control: A Multicenter 6-Month Trial of 24/7 Automated Insulin DeliveryBoris Kovatchev, Peiyao Cheng, Stacey M Anderson, et al.
Diabetes Technology & Therapeutics|October 18, 2023
Two Years with a Tubeless Automated Insulin Delivery System: A Single-Arm Multicenter Trial in Children, Adolescents, and Adults with Type 1 DiabetesAmy B Criego, Anders L Carlson, Sue A Brown, et al.
Pageof 7

Showing results (51-60 of 65) with videos related to

Sort By:
Pageof 7
Diabetes Technology & Therapeutics|May 17, 2019
Hybrid Closed-Loop Control Is Safe and Effective for People with Type 1 Diabetes Who Are at Moderate to High Risk for HypoglycemiaStacey M Anderson, Bruce A Buckingham, Marc D Breton, et al.
Pediatric Diabetes|November 22, 2017
Predictive hyperglycemia and hypoglycemia minimization: In-home double-blind randomized controlled evaluation in children and young adolescentsGregory P Forlenza, Dan Raghinaru, Faye Cameron, et al.
Diabetes Technology & Therapeutics|August 14, 2023
Automated Insulin Delivery with Remote Real-Time Continuous Glucose Monitoring for Hospitalized Patients with Diabetes: A Multicenter, Single-Arm, Feasibility TrialGeorgia M Davis, Michael S Hughes, Sue A Brown, et al.
Diabetes, Obesity & Metabolism|September 20, 2024
Psychosocial outcomes with the Omnipod® 5 Automated Insulin Delivery System in caregivers of very young children with type 1 diabetesSarah A MacLeish, Korey K Hood, William H Polonsky, et al.
The Lancet. Diabetes & Endocrinology|February 26, 2026
Tubeless automated insulin delivery versus multiple daily injections in children and adults with type 1 diabetes with elevated HbA<sub>1c</sub> (RADIANT): a multicentre, international, parallel-group, open-label, randomised, controlled trialEmma G Wilmot, Jacques Beltrand, Bruno Guerci, et al.
Diabetes Care|July 18, 2025
Use of the Omnipod 5 Automated Insulin Delivery System Activity Feature Reduces Insulin Delivery and Attenuates the Drop in Glycemia Associated With Exercise in a Randomized Controlled TrialLauren V Turner, Jennifer L Sherr, Dessi P Zaharieva, et al.
Pediatric Diabetes|April 30, 2025
Psychosocial Outcomes with the Omnipod® 5 Automated Insulin Delivery System in Children and Adolescents with Type 1 Diabetes and Their CaregiversKorey K Hood, William H Polonsky, Sarah A MacLeish, et al.
Diabetes Research and Clinical Practice|July 19, 2022
How introduction of automated insulin delivery systems may influence psychosocial outcomes in adults with type 1 diabetes: Findings from the first investigation with the Omnipod® 5 SystemWilliam H Polonsky, Korey K Hood, Carol J Levy, et al.
Diabetes Technology & Therapeutics|December 17, 2016
Feasibility of Long-Term Closed-Loop Control: A Multicenter 6-Month Trial of 24/7 Automated Insulin DeliveryBoris Kovatchev, Peiyao Cheng, Stacey M Anderson, et al.
Diabetes Technology & Therapeutics|October 18, 2023
Two Years with a Tubeless Automated Insulin Delivery System: A Single-Arm Multicenter Trial in Children, Adolescents, and Adults with Type 1 DiabetesAmy B Criego, Anders L Carlson, Sue A Brown, et al.
Pageof 7